* travel history / residence history of wuhan city and surrounding areas, or other communities with case reports within 14 days; * history of contact with a sars-cov-2 infection (positive in nucleic acid test) within 14 days; * have contacted patients with fever or respiratory symptoms from wuhan and surrounding areas, or from communities with case reports within 14 days; * have contacted patients with fever or respiratory symptoms from wuhan and surrounding areas, or from communities with case reports within 14 days; * self-reported history of sars; * self-reported history of new coronavirus infection; * positive in serum antibodies (igg or igm) screening of covid-19; * positive in nasopharyngeal swabs or anal swabs through rt-pcr; * women who are breastfeeding, pregnant or planning to become pregnant during the study period; * bmi≥35 kg/m2; * history of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema; * congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; * autoimmune disease or immunodeficiency / immunosuppression; * suffering from severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver and kidney diseases, malignant tumors, etc.; * severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; * thyroid disease or history of thyroidectomy, spleenlessness, functional spleenlessness, spleenlessness or splenectomy resulting from any condition; * diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation; * immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute non-complicated dermatitis superficial corticosteroid therapy) in the past 6 months; * abnormal laboratory test results in the physical examination such as clinically significant abnormal hematology and biochemistry beyond the reference value range (only applicable to phase i clinical trials); * history of alcohol or drug abuse; * receipt of blood products within in the past 3 months; * receipt of other investigational drugs in the past 30 days; * receipt of attenuated live vaccines in the past 14 days; * receipt of inactivated or subunit vaccines in the past 7 days; * attacks of acute diseases or chronic diseases in the past 7 days; * axillary temperature \>37.0°c; * according to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

* travel history / residence history of wuhan city and surrounding areas, or other communities with case reports within 14 days; * history of contact with a sars-cov-2 infection (positive in nucleic acid test) within 14 days; * have contacted patients with fever or respiratory symptoms from wuhan and surrounding areas, or from communities with case reports within 14 days; * have contacted patients with fever or respiratory symptoms from wuhan and surrounding areas, or from communities with case reports within 14 days; * self-reported history of sars; * self-reported history of new coronavirus infection; * positive in serum antibodies (igg or igm) screening of covid-19; * positive in nasopharyngeal swabs or anal swabs through rt-pcr; * women who are breastfeeding, pregnant or planning to become pregnant during the study period; * bmi≥35 kg/m2; * history of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema; * congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; * autoimmune disease or immunodeficiency / immunosuppression; * suffering from severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver and kidney diseases, malignant tumors, etc.; * severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; * thyroid disease or history of thyroidectomy, spleenlessness, functional spleenlessness, spleenlessness or splenectomy resulting from any condition; * diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation; * immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute non-complicated dermatitis superficial corticosteroid therapy) in the past 6 months; * abnormal laboratory test results in the physical examination such as clinically significant abnormal hematology and biochemistry beyond the reference value range (only applicable to phase i clinical trials); * history of alcohol or drug abuse; * receipt of blood products within in the past 3 months; * receipt of other investigational drugs in the past 30 days; * receipt of attenuated live vaccines in the past 14 days; * receipt of inactivated or subunit vaccines in the past 7 days; * attacks of acute diseases or chronic diseases in the past 7 days; * axillary temperature \>37.0°c; * according to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

- travel history / residence history of wuhan city and surrounding areas, or other communities with case reports within 14 days; - history of contact with a sars-cov-2 infection (positive in nucleic acid test) within 14 days; - have contacted patients with fever or respiratory symptoms from wuhan and surrounding areas, or from communities with case reports within 14 days; - have contacted patients with fever or respiratory symptoms from wuhan and surrounding areas, or from communities with case reports within 14 days; - self-reported history of sars; - self-reported history of new coronavirus infection; - positive in serum antibodies (igg or igm) screening of covid-19; - positive in nasopharyngeal swabs or anal swabs through rt-pcr; - women who are breastfeeding, pregnant or planning to become pregnant during the study period; - bmi≥35 kg/m2; - history of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema; - congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; - autoimmune disease or immunodeficiency / immunosuppression; - suffering from severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver and kidney diseases, malignant tumors, etc.; - severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; - thyroid disease or history of thyroidectomy, spleenlessness, functional spleenlessness, spleenlessness or splenectomy resulting from any condition; - diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation; - immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute non-complicated dermatitis superficial corticosteroid therapy) in the past 6 months; - abnormal laboratory test results in the physical examination such as clinically significant abnormal hematology and biochemistry beyond the reference value range (only applicable to phase i clinical trials); - history of alcohol or drug abuse; - receipt of blood products within in the past 3 months; - receipt of other investigational drugs in the past 30 days; - receipt of attenuated live vaccines in the past 14 days; - receipt of inactivated or subunit vaccines in the past 7 days; - attacks of acute diseases or chronic diseases in the past 7 days; - axillary temperature >37.0°c; - according to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

- travel history / residence history of wuhan city and surrounding areas, or other communities with case reports within 14 days; - history of contact with a sars-cov-2 infection (positive in nucleic acid test) within 14 days; - have contacted patients with fever or respiratory symptoms from wuhan and surrounding areas, or from communities with case reports within 14 days; - have contacted patients with fever or respiratory symptoms from wuhan and surrounding areas, or from communities with case reports within 14 days; - self-reported history of sars; - self-reported history of new coronavirus infection; - positive in serum antibodies (igg or igm) screening of covid-19; - positive in nasopharyngeal swabs or anal swabs through rt-pcr; - women who are breastfeeding, pregnant or planning to become pregnant during the study period; - bmi≥35 kg/m2; - history of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema; - congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; - autoimmune disease or immunodeficiency / immunosuppression; - suffering from severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver and kidney diseases, malignant tumors, etc.; - severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; - thyroid disease or history of thyroidectomy, spleenlessness, functional spleenlessness, spleenlessness or splenectomy resulting from any condition; - diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation; - immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute non-complicated dermatitis superficial corticosteroid therapy) in the past 6 months; - abnormal laboratory test results in the physical examination such as clinically significant abnormal hematology and biochemistry beyond the reference value range (only applicable to phase i clinical trials); - history of alcohol or drug abuse; - receipt of blood products within in the past 3 months; - receipt of other investigational drugs in the past 30 days; - receipt of attenuated live vaccines in the past 14 days; - receipt of inactivated or subunit vaccines in the past 7 days; - attacks of acute diseases or chronic diseases in the past 7 days; - axillary temperature >37.0°c; - according to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.